BNB Treasury Company WINT Will Be Delisted Due to Failure to Meet Nasdaq Listing Standards

Nasdaq has decided to suspend trading of Windtree Therapeutics (WINT) common stock, effective at the opening of trading on August 21, 2025, and to initiate delisting procedures for Windtree Therapeutics (WINT), due to its failure to comply with Nasdaq Listing Rule 5550(a)(2). Trading of the company's common stock will transition to the OTC market under the same symbol as WINT. Windtree Therapeutics has applied for listing on the OTCID segment, but approval is not guaranteed. The company's business and operations remain unaffected, and it will continue to file periodic reports with the SEC.